11.37
+0.18(+1.61%)
Currency In USD
| Previous Close | 11.19 |
| Open | 11.34 |
| Day High | 11.57 |
| Day Low | 11.16 |
| 52-Week High | 76 |
| 52-Week Low | 6.34 |
| Volume | 3,586 |
| Average Volume | 15,306 |
| Market Cap | 53.37M |
| PE | -3.78 |
| EPS | -3.01 |
| Moving Average 50 Days | 11.87 |
| Moving Average 200 Days | 12.57 |
| Change | 0.18 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $94.75 as of February 21, 2026 at a share price of $11.37. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $560.1 as of February 21, 2026 at a share price of $11.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
GlobeNewswire Inc.
Feb 04, 2026 2:30 AM GMT
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXING
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
GlobeNewswire Inc.
Jan 08, 2026 5:00 PM GMT
Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
GlobeNewswire Inc.
Nov 20, 2025 4:42 PM GMT
MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to generate potent, lasting anti-tumor activity in l